Tissue factor and chemotherapy resistance in neuroblastoma cells
Author Information
Author(s): Fang Jun, Gu Lubing, Zhu Ningxi, Tang Hao, Alvarado Carlos S, Zhou Muxiang
Primary Institution: Emory University School of Medicine
Hypothesis
The interaction between tissue factor (TF) and factor VIIa (FVIIa) regulates chemotherapy resistance in neuroblastoma cell lines.
Conclusion
The study shows that the TF/FVIIa pathway contributes to chemotherapy resistance in neuroblastoma by upregulating Bcl-2 through the JAK/STAT5 signaling pathway.
Supporting Evidence
- TF expression was variable among neuroblastoma cell lines, with SH-EP1 cells showing high levels and SK-N-SH cells lacking TF.
- SH-EP1 cells were more resistant to doxorubicin than SK-N-SH cells.
- Silencing TF in SH-EP1 cells sensitized them to doxorubicin-induced apoptosis.
- Transfection of TF into SK-N-SH cells increased resistance to doxorubicin when treated with FVIIa.
- JAK inhibitor blocked the TF/FVIIa-induced upregulation of Bcl-2.
Takeaway
This study found that a protein called tissue factor helps cancer cells survive chemotherapy by making them resistant to a drug called doxorubicin.
Methodology
Gene and siRNA transfection were used to manipulate TF expression in neuroblastoma cell lines, followed by Western blot assays and cytotoxicity tests.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website